| Name | Title | Contact Details |
|---|---|---|
Andrew Schafer |
Chief Technology Officer | Profile |
Montesino Associates is a Sparta, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clementia is a biopharmaceutical company that is focused on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease. Our lead program is palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.
Knopp Neurosciences is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.